Survival Analysis of Breast Cancer in Patients with HER2/neu+, ER-, PR-: a Retrospective Cohort Study

Figures & data

Table 1. Characteristics of the patients with HER2+/ER-/PR- breast cancer (n = 119).

Variable		Frequency	Percentage
Age (year)	<30	1	0.84
	30–39	13	10.92
	40–49	30	25.21
	50–59	44	36.97
	60–69	20	16.81
	≥70	11	9.24
Type of cancer	Ductal carcinoma in situ	13	11.02
	Invasive ductal carcinoma	95	80.51
	Invasive lobular carcinoma	9	7.63
	Mixed invasive ductal lobular carcinoma	1	0.85
Stage	I	24	22.86
	II	44	41.90
	III	36	34.29
	IV	1	0.95
Grade	I	5	4.63
	II	46	42.59
	III	57	52.78
Tumor size (cm)	<2	33	28.70
	2–3	49	42.61
	>3 and ≤5	29	25.22
	>5	4	3.48
Recurrence	No	109	93.27
	Yes	8	6.73
Distal metastasis	No	105	88.24
	Yes	14	11.76
Site of metastasis/recurrence	Skin/breast (recurrence)	8	36.36
	Brain	2	9.09
	Bone	2	9.09
	Visceral (lungs and liver)	10	45.45
Lymph vascular involvement	No	64	54.24
	Yes	54	45.76
Number of removed lymph nodes	<10	57	50
	≥10	57	50
Number of positive nodes	N0	59	51.75
	N1 (1–3)	22	19.30
	N2 (4–9)	17	14.91
	N3 (≥10)	16	14.04
Sentinel node procedure	Yes	73	61.86
	No	45	38.14
Sentinel node result	Positive	24	32.88
	Negative	49	67.12

Table 2. Risk of recurrence and death based on tumor characteristics, based on the univariate analysis.

	Variables	Recurrence		Mortality
		Hazard ratio	p-value	Hazard ratio	p-value
Stage	I	Reference	–	Reference	–
	II	0.81 (0.22–2.09)	0.75	1.07 (0.09–2.83)	0.09
	III	1.04 (0.29–3.06)	0.95	3.66 (2.06–5.49)	0.02
	IV	3.32 (0.36–1.41)	0.29	10.03 (0.2–14.49)	0.11
Grade	I	Reference	–	Reference	–
	II	0.51 (0.1–4.99)	0.3	0.43 (0.12–2.11)	0.36
	III	0.6 (0.26–2.13)	0.45	0.81 (0.18–7.04)	0.82
Pathological type	Ductal carcinoma in-situ	Reference	–	–	–
	Invasive ductal carcinoma	1.02 (0.91–7.12)	0.98	–	–
	Invasive lobular carcinoma	3(0.55–6.01)	0.23	–	–
	Mixed invasive ductal and lobular carcinoma	–	–	–	–
Neoadjuvant chemotherapy	No	Reference	0.3	Reference	0.001
	Yes	1.93 (0.90–2.04)		79.04 (61.11–83.70)
Mortality	No	Reference	0.26	–	–
	Yes	2.65 (0.28–3.23)

Table 3. Overall survival based on metastasis site.

Site of the metastasis	Overall survival, month
	Mean	SD	Min	Max
Local (skin/breast) metastasis	81.77	56.80	41.60	121.93
Brain metastasis	30.88	11.90	22.47	39.3
Bone metastasis	45.20	–	45.20	45.20
Lung and liver (visceral) metastasis	30.55	24.43	3.10	58.47

Figure 1. Overall survival of the patients with HER2/neu+, ER- and PR-breast cancer.

Figure 2. Disease-free survival of the patients with HER2/neu+, ER- and PR- breast cancer.